Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › Informatics › OpGen, Merck to Co-Develop Antibiotic Resistance Dx, Informatics

OpGen, Merck to Co-Develop Antibiotic Resistance Dx, Informatics

Nov 14, 2016
|
staff reporter

NEW YORK (GenomeWeb) – OpGen and Merck announced today that they will collaborate to develop rapid diagnostics and informatics tools for antibiotic resistance.

Under the terms of the deal, Merck will give OpGen access to its library of 200,000 bacterial pathogens in order to support OpGen's development of rapid DNA tests and a genomic database of antibiotic-resistant pathogens.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
26
Featured Webinar

Responding to Emerging SARS-CoV-2 Variants: The Impact on Existing Diagnostic Testing and the Clinical Utility of Differentiation Assays

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.  

What's Popular?

In Molecular Diagnostics

  1. Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests

  2. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

  3. Jonathan Rothberg-Led Startup Looks to Bring Disposable POC SARS-CoV-2 Test to Market

    Premium

  4. CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon

  5. Invitae to Raise $400M in Proposed Public Offering

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.